A5047411304- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Health Systems, Economic Evaluations, Quality of Life
- Acute Ischemic Stroke Management
- Genetics, Aging, and Longevity in Model Organisms
- Functional Brain Connectivity Studies
- Epigenetics and DNA Methylation
- Circadian rhythm and melatonin
- Cancer-related cognitive impairment studies
- Diet and metabolism studies
- Frailty in Older Adults
- Amyotrophic Lateral Sclerosis Research
- Autophagy in Disease and Therapy
Lund University
2022-2025
University of Copenhagen
2023
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status predict future progression dementia. The study included 135 patients with baseline diagnosis mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average 4.9 years. Seventy-one participants had...
Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarker for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance unclear. We compared key plasma tests using cross-sectional and longitudinal measures amyloid-β (Aβ)-PET, tau-PET, cognition as outcomes, benchmarked them against cerebrospinal fluid (CSF) tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53%...
Abstract INTRODUCTION We evaluated differences in p‐tau levels between Alzheimer's disease (AD), a condition with brain‐specific changes p‐tau, and amyotrophic lateral sclerosis (ALS), associated increases peripheral levels. METHODS Cerebrospinal fluid plasma from 668 participants were analyzed using immunoassays specific for the low‐molecular‐weight (LMW) tau isoforms present brain (i.e., p‐tau217 Lilly , p‐tau181 ) those that detect both LMW‐ high‐molecular‐weight (HMW) expressed nervous...
Studies suggest that cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)42 and Aβ40 present a circadian rhythm. However sustained sampling large volumes CSF with indwelling intrathecal catheters used in most these studies might have affected dynamics thereby confounded the observed fluctuations biomarker levels.
Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance unclear. We compared key plasma tests using cross-sectional and longitudinal measures amyloid-β (Aβ)-PET, tau-PET, cognition as outcomes, benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age...
The growing prevalence of Alzheimer's disease (AD) is becoming a global health challenge without effective treatments. Defective mitochondrial function and mitophagy have recently been suggested as etiological factors in AD, association with abnormalities components the autophagic machinery like lysosomes phagosomes. Several large transcriptomic studies performed on different brain regions from AD healthy patients, their data represent vast source important information that can be utilized...
Abstract Background Studies suggest that cerebrospinal fluid (CSF) levels of Alzheimer’s disease (AD) biomarkers, amyloid‐β (Aβ) and tau, follow a circadian rhythm. However sustained sampling CSF with indwelling intrathecal catheter used in most these studies might have affected the observed fluctuations biomarker levels. Methods We included 38 individuals either normal (N = 18) or abnormal 20) Aβ42/40 status. plasma were collected, at same occasion, two different visits separated by an...